Back to Newsroom

Forbes: Company Run By 30-Year-Old Former Hedge Fund Manager Starts Study To Get Its Alzheimer’s Drug Approved

Matthew Herper

Oct 6, 2015

Axovant Sciences, the Alzheimer’s startup founded by former hedge fund manager Vivek Ramaswamy, announced this morning that it has begun a 1,150-patient study aimed at getting RVT-101, the Alzheimer’s drug that the company purchased from GlaxoSmithKline , approved by the Food and Drug Administration.

In another positive step for the company, Axovant announced that the FDA has granted it a special protocol assessment, or SPA, an agreement that means the agency agrees that the study, if successful, would provide adequate evidence for an approval of the drug.

Click here to read the full article